Saved in:
| Main Author: | |
|---|---|
| Format: | Artículo científico |
| Language: | fr |
| Published: |
Vilniaus Universitetas
2016
|
| Subjects: | |
| Online Access: | https://www.redalyc.org/articulo.oa?id=694073987006 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience Edita Baltruškevičienė Ugnius Mickys Tadas Žvirblis Rokas Stulpinas Teresė Pipirienė Želvienė Eduardas Aleknavičius Medicina KRAS BRAF NRAS PIK3CA bevacizumab KRAS mutation is an important predictive and prognostic factor for patients receiving anti-EGFR therapy. An expanded KRAS, NRAS, BRAF, PIK3CA mutation analysis provides additional prognostic information, but its role in predicting bevacizumab efficacy is unclear. T he aim of our study was to evaluate the incidence of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving f irst line oxaliplatin based chemotherapy with or without bevacizumab and to evaluate their prognostic and predictive significance. 2016 artículo científico 2029-4174 https://www.redalyc.org/articulo.oa?id=694073987006 fr http://www.redalyc.org/revista.oa?id=6940 Acta medica Lituanica application/pdf Vilniaus Universitetas Acta medica Lituanica (Lituania) Num.1 Vol.23